Serum CA 19?9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests
| ISSN: | 1591-9528 1591-8890 |
|---|---|
| DOI: | 10.1007/s10238-003-0014-z |
| Přístupová URL adresa: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80600f512654d7de7bb08e6688b20e36 https://doi.org/10.1007/s10238-003-0014-z |
| Rights: | CLOSED |
| Přírůstkové číslo: | edsair.doi.dedup.....80600f512654d7de7bb08e6688b20e36 |
| Autor: | A. Augarten, Y. Yahav, L. Ben Tur, Hannah Blau, Amir Szeinberg, A. Diver-Habber, H. Berman, Hannah Akons, D. Katznelson, Joseph Rivlin, Eitan Kerem, Micha Aviram, L. Theodor, Gideon Paret, Batsheva Kerem |
| Rok vydání: | 2003 |
| Předmět: |
Adult
Pathology medicine.medical_specialty Pancreatic disease Adolescent CA-19-9 Antigen Cystic Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator Cystic fibrosis Gastroenterology General Biochemistry Genetics and Molecular Biology Pulmonary function testing Electrolytes Liver disease Diabetes mellitus Internal medicine medicine Humans Child Sweat Sweat test medicine.diagnostic_test business.industry General Medicine medicine.disease Mutation Pancreatitis CA19-9 business |
| Zdroj: | Clinical and Experimental Medicine. 3:119-123 |
| ISSN: | 1591-9528 1591-8890 |
| DOI: | 10.1007/s10238-003-0014-z |
| Popis: | Patients with normal or borderline sweat tests present a diagnostic challenge. In spite of the availability of genetic analysis and measurement of nasal potential difference, there is still uncertainty in diagnosing cystic fibrosis in some patients. CA 19-9 is a tumor-associated antigen whose levels were previously found to be elevated in some cystic fibrosis patients. We investigated whether serum CA 19-9 levels can contribute to establishing the diagnosis of cystic fibrosis in patients with a borderline sweat test, and evaluated the influence of different clinical variables on CA 19-9 levels. Serum CA 19-9 levels were measured in 82 cystic fibrosis patients grouped according to their genotype and in 38 healthy individuals. Group A included 50 patients who carried two mutations previously found to be associated with a pathological sweat test and pancreatic insufficiency (DeltaF508, W1282X, G542X, N1303K, and S549R). Group B included 13 compound heterozygote cystic fibrosis patients who carried one mutation known to cause mild disease with a borderline or normal sweat test and pancreatic sufficiency (3849+10kb C-->T, 5T). Group C included 38 normal controls. Nineteen cystic fibrosis patients carried at least one unidentified mutation. An association between CA 19-9 levels and age, pulmonary function, pancreatic status, sweat chloride, previous pancreatitis, serum lipase, meconium ileus, distal intestinal obstruction, liver disease, and diabetes was investigated. The distribution of CA 19-9 levels was significantly different between the three groups ( p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink